204 results about "Metal Chelator" patented technology

Drug formulations for systemic drug delivery with improved stability and rapid onset of action are described herein. The formulations may be administered via buccal administration, sublingual administration, pulmonary delivery, nasal administration, subcutaneous administration, rectal administration, vaginal administration, or ocular administration. In the preferred embodiments, the formulations are administered sublingually or via subcutaneous injection. The formulations contain an active agent and one or more excipients, selected to increase the rate of dissolution. In the preferred embodiment, the drug is insulin, and the excipients include a metal chelator such as EDTA and an acid such as citric acid. Following administration, these formulations are rapidly absorbed by the oral mucosa when administered sublingually and are rapidly absorbed into the blood stream when administered by subcutaneous injection. In one embodiment, the composition is in the form of a dry powder. In another embodiment, the composition is in the form of a film, wafer, lozenge, capsule, or tablet. In a third embodiment, a dry powdered insulin is mixed with a diluent containing a pharmaceutically acceptable carrier, such as water or saline, a metal chelator such as EDTA and an acid such as citric acid. Devices for storing and mixing these formulations are also described.

Nucleotide delivery polymers, compositions, and associated methods for the enhancement of gene delivery and expression in solid tissues are provided. In one aspect, for example, a nucleotide delivery polymer may include a poloxamer backbone having a metal chelator covalently coupled to at least one terminal end of the poloxamer backbone. In another aspect, the nucleotide expression polymer has a metal chelator coupled to at least two terminal ends of the poloxamer backbone.

Disclosed are methods and devices for detection of ion migration and binding, utilizing a nanopipette adapted for use in an electrochemical sensing circuit. The nanopipette may be functionalized on its interior bore with metal chelators for binding and sensing metal ions or other specific binding molecules such as boronic acid for binding and sensing glucose. Such a functionalized nanopipette is comprised in an electrical sensor that detects when the nanopipette selectively and reversibly binds ions or small molecules. Also disclosed is a nanoreactor, comprising a nanopipette, for controlling precipitation in aqueous solutions by voltage-directed ion migration, wherein ions may be directed out of the interior bore by a repulsing charge in the bore.

New and improved compounds for use in diagnostic imaging or therapy having the formula M-N—O—P-G, wherein M is a metal chelator having the structure:

wherein R1-R5 and FG are as defined herein (in the form complexed with a metal radionuclide or not), N—O—P is the linker containing at least one non-alpha amino acid with a cyclic group, at least one substituted bile acid or at least one non-alpha amino acid, and G is the GRP receptor targeting peptide. In the preferred embodiment, M is an Aazta metal chelator or a derivative thereof.

Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided. Novel methods of treating prostate tumors or of delaying the progression of prostate tumors are also provided, including, methods of treating bone or soft tissue metastases of prostate cancer, methods for treating hormone sensitive and hormone refractory prostate cancer, methods for delaying the progression of hormone sensitive prostate cancer, for facilitating combination therapy in patients with hormone sensitive prostate cancer and for decreasing aberrant vascular permeability in patients with hormone sensitive prostate cancer.

Methods and compositions for preventing oxidative damage to proteins, particularly antibodies, are provided. The compositions include a combination of metal chelators, such as DTPA, EGTA, and/or DEF, and can further include one or more free radical scavengers, particularly scavengers of oxygen radicals. Methods for enhancing protein stability using the compositions of the invention are also disclosed.

A resveratrol-containing composition capable of providing a therapeutic benefit to a subject such as modulation of a biological activity, improving cell transplantation therapy, or improving macular degeneration or dystrophy treatments. The compositions comprise trans-resveratrol, a metal chelator, and one or more additional antioxidants such as phenolic antioxidants or vitamin D.

The present invention provides prodrugs comprising a polymer conjugated to a metal chelator via a disulfide bond. For example, D-penicillamine may be conjugated to a polymer (e.g., gelatin, chitosan, polyglutamic acid) via a linker, such as SPDP. Thus, the cellular delivery and pharmacokinetics of D-penicillamine can be substantially improved. Methods for the treatment of cancer using compositions of the present invention are also disclosed.

New and improved compounds for use in diagnostic imaging or therapy having the formula M-N-O-P-G, wherein M is a metal chelator having the structure: wherein R1-R5 and FG are as defined herein (in the form complexed with a metal radionuclide or not), N-O-P is the linker containing at least one non-alpha amino acid with a cyclic group, at least one substituted bile acid or at least one non-alpha amino acid, and G is the GRP receptor targeting peptide. In the preferred embodiment, M is an Aazta metal chelator or a derivative thereof. Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided.

The present invention provides supramolecular hydrogels having a three-dimensional, self-assembling, elastic, network structure comprising non-polymeric, functional molecules and a liquid medium, whereby the functional molecules are noncovalently crosslinked. The functional molecules may be, for instance, anti-inflammatory molecules, antibiotics, metal chelators, anticancer agents, small peptides, surface-modified nanoparticles, or a combination thereof. Applications of the present invention include use of the supramolecular hydrogel, for instance, as a biomaterial for wound healing, tissue engineering, drug delivery, and drug/inhibitor screening.

The present invention provides a metal chelator and methods that facilitate binding, detecting, monitoring and quantitating of zinc ions in a sample. The metal chelating moiety of the zinc-binding compound is an analog of the well-known calcium chelator, BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N′N′-tetraacetic acid), wherein the chelating moiety has been modified from a tetraacetic acid moiety to a tri- di- or monoacetic moiety. This change in acetic acid groups on the metal chelating moiety results in the selective bindings of zinc ions in the presence of calcium ions, both of which are present in biological fluids and intracellular cytosolic fluid and organelles.

The invention discloses a synchronous desulphrization and denitration method of flue gas pyrolusite pulp for reclamation. The method mainly comprises the following steps: pyrolusite, water and metal-chelator are prepared into pulp which is taken as an absorbing agent; sulfur dioxide and nitrogen oxides in the flue gas are synchronously absorbed and removed by the absorbing agent; the flue gas is discharged when the purification reaches a standard; the primary product of the mixed mother solution of manganese sulfate and manganese nitrate is obtained after absorbing tail solution is purified; and by utilizing the different solubility of manganese sulfate and manganese nitrate at same temperature, the mixed mother solution is heated firstly to cause the manganese sulfate therein to be crystallized and separated, next, the left mother solution is cooled to cause the manganese nitrate therein to be crystallized and separated, and the left solution is returned to preparation pulp for recycling. No waster water is discharged in the whole process, thereby achieving the purposes of controlling waste by waste, recycling sulfur resources and improving the comprehensive utilization value of pyrolusite. The method is characterized by high desulphrization and denitration efficiency and manganese utilization rate, little secondary pollution, obvious economic benefit and the like.

The invention belongs to the technical field of soil environment treatment, and particularly relates to a heavy metal immobilization chemical reagent composition and a treatment method of heavy metal in immobilization polluted soil. The immobilized reagent composition comprises phosphate chemical compound of 5-70%, metal sulfide of 1-60%, metal oxide of 5-80%, strong alkali and weak acid salt of 5-65%, metal stabilizers of 0.1-15% and metal chelator of 0.1-10%. The invention further provides a method of restoring heavy metal polluted soil in an immobilization mode by immobilized reagents. The immobilized reagents can enable various heavy metal pollutants in the polluted soil to be immobilized, the content of activated state (transportable) heavy metal in soil is lowered, and restoration and treatment to the heavy metal polluted soil are achieved. The heavy metal pollutant immobilized reagent composition and the immobilization treatment method have the advantages of being good in immobilization effect, simple and easy in operating process, low in cost, and free of secondary pollution and the like.

Stabilized albuterol compositions are provided. The compositions are aqueous inhalation compositions containing albuterol; a buffer, such as citric acid; and a metal chelator, such as EDTA.

The invention relates to a preparation method of transition metal doped carbon fluorescent quantum dots. According to the method, a metal chelator and transition metal salt are dissolved in an organicphase and water which are incompatible with each other, then, a heating reaction is conducted, concentration and purification are performed after the reaction, and transition metal doped carbon fluorescent quantum dots with different solubility are prepared. The method is convenient to operate, doping of carbon fluorescent quantum dots with metal ions can be realized without harsh reaction conditions or large instruments. The obtained carbon dots have multiple different characteristics according to different types of doping metal ions and different solvents. The prepared carbon dots have great application value in preparation of bio-labeling sensing and medical imaging, photoelectric and light-emitting devices and the like due to these characteristics.

The invention relates to a dry preparation method of transition metal doped carbon fluorescent quantum dots. According to the method, a metal chelator and transition metal salt are subjected to a thermal reaction in the absence of a solvent, and the transition metal doped carbon fluorescent quantum dots are prepared with extraction, centrifugation and dialysis methods after the reaction. The method is convenient to operate, doping of carbon fluorescent quantum dots with metal ions can be realized without harsh reaction conditions or large instruments, and the obtained carbon dots have good water solubility and wider fluorescence emission ranges. The obtained carbon dots have multiple different characteristics according to different types of doping metal ions and different solvents. The prepared carbon dots have great application value in preparation of bio-labeling sensing and medical imaging, photoelectric and light-emitting devices and the like due to these characteristics.

The present invention relates to methods of treating an allergic or non-allergic respiratory disorder by administering orally a composition of lactoferrin alone or in combination with metal chelators to treat respiratory disorders.